Keynote Speakers:

Clinical Impact of Anti-Drug Antibodies

Meena Subramanyam, Ph.D., Senior Director, Clinical Science & Technology, Biogen Idec, Inc.

Priorities for EU Guidance on Immunogenicity Risk Assessment for Therapeutic Monoclonal Antibodies

Paul Chamberlain, NDA Advisory Board

Pre-clinical Studies and Clinical Plans for Tolerance Induction

Richard Garman, Ph.D., Scientific Director, Immunology R&D, Genzyme Corp.

Featured Presentations:

• Gopi Shankar, Ph.D., Director, Clinical Pharmacology Sciences, Centoc R&D, Inc.
• Bonnie Rup, Ph.D., Assistant Vice President, Protein Bioanalytics, Drug Safety and Metabolism, Wyeth Research
• Michael G. Tovey, Ph.D., Director of Research, Laboratory of Viral Oncology, Institute Andre Lwoff, CNRS
• Susan Kirshner, Associate Chief, Laboratory of Immunology, Office of Biotechnology, FDA
• Boris Gorovits, Ph.D., Director, Drug Safety Metabolism, Bioanalytical R&D, Wyeth
• Matthew Baker, Ph.D., Chief Scientific Officer, Antitope Ltd.

Distinguished Faculty List:

• Michele Fiscella, Ph.D., Associate Director, Clinical Immunology Department, Human Genome Sciences
• Dong Geng, Principal Scientist, Bioanalytical Sciences, Bristol-Myers Squibb Co.
• Bonnie Wu, Ph.D., Senior Research Scientist, Clinical Pharmacology Sciences, Centocor Research & Development, Inc.
• Meina Liang, Ph.D., Associate Director, PKPD & Bioanalysis, MedImmune, Inc.
• Joy Cavagnaro, Ph.D., D.A.B.T., R.A.C., President, Access BIO, LC
• Nadja S. Prang-Richard, Ph.D., M.B.A., Program Director Monoclonal Antibodies, LFB S.A.
• Jochem Gokemeijer, Principal Scientist, Pharmacology, Adnexus Therapeutics, a Bristol-Myers Squibb R&D Company
• Claire Dobson, Ph.D., Head of Display Technology - Neuroscience & CVGI, Lead Generation, MedImmune, Inc.
• Sally Fischer, Ph.D., Senior Scientist / Group Leader, Bioanalytical Research and Development (BARD), Genentech, Inc.
• Erik D. Foehr, Ph.D., Director, BioAnalytical Research and Development, BioMarin Pharmaceuticals, Inc.
• Albert Torri, Ph.D., Senior Director, Pre-clinical Development, Regeneron Pharmaceuticals, Inc.
• Steve Keller, Director, Pre-clinical and Clinical Development Sciences, Facet Biotech, Inc.
• Joël Richard, Ph.D., Senior Director, Head of Drug Product Development, Pharmaceutical Development, IPSEN - Beaufour Ipsen Industrie
• Jack A. Ragheb, M.D., Ph.D., Senior Regulatory Research Officer, Laboratory of Immunology, Department of Therapeutic Proteins, CDER, FDA. (Tentative)
• Richard Garman, Ph.D., Scientific Director, Immunology R&D, Genzyme
• Barend Bouma, Ph.D., Chief Operating Officer, Head Research & Development, Crossbeta Biosciences BV
• Volker Schellenberger, Ph.D., Vice President, Drug Discovery, Amunix, Inc.
• Philippe Stas, MBA, CEO, Algonomics
• Fiona A. Harding, Ph.D., Associate Director, New Technologies, Facet Biotech, Inc.
• David Estell, Vice President, Innovation, Genencor International
• Erika Gustafsson, Ph.D., Project Manager, Alligator Bioscience
• Kathleen M. Williams, Ph.D, J.D., Intellectual Property Law, Edwards Angell Palmer & Dodge LLP